Amgen Signs an Immuno-Oncology Agreement with Molecular Partners’ for its MP0310

 Amgen Signs an Immuno-Oncology Agreement with Molecular Partners’ for its MP0310

Amgen Signs an Immuno-Oncology Agreement with Molecular Partners’ for its MP0310

Shots:
  • Molecular to receive $50M upfront, $497M milestone and royalties on sales and also has certain rights to commercialize DARPin based products with MP0310. Amgen to get exclusive worldwide development and commercialization rights for Molecular’s MP0310
  • The companies will jointly evaluate MP0310 with Amgen’s oncology product and BiTE (bispecific T cell engager) molecules, with defined cost sharing for first three indications
  • Molecular’s MP0310 is a pre-clinical, FAP x 4-1BB DARPin Molecule, targeted for activation of
    immune cells in tumor by binding FAP & T cells via 4-1BB (immune modulator)\

Click here to read full press release/ article | Ref: Amgen | Image: CNBC

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post